Drugs / Contezolid
Contezolid
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06811025 | Feb 2024 → Dec 2025 overdue | meningitis, tuberculosis | Beijing Chest Hospital | Enrolling by invitation | No outcome recorded |
| Phase 1/2 | NCT06811012 | Jan 2024 → Dec 2025 overdue | disease of bone structure, tuberculosis | Beijing Chest Hospital | Enrolling by invitation | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT07372781 | Jan → Dec 2026 expected | mycobacterial infectious disease | Beijing Chest Hospital | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT02269319 | Feb → Aug 2015 | bacterial infectious disease | MicuRx | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT06081361 | Dec 2023 → Oct 2026 expected | pulmonary tuberculosis, rifampicin-resistant tuberculosis | Beijing Chest Hospital | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05369052 | May 2022 → Jun 2026 overdue | — | MicuRx | Recruiting | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT07213765 | Jul 2025 → Sep 2028 expected | Mycobacterium avium complex disease | Bin Cao | Recruiting | No outcome recorded |
| Phase 4 | NCT07084402 | Jul 2025 → Jul 2027 expected | Mycobacterium avium complex disease | Bin Cao | Recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | contezolid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05369052 ↗ |
| Known as | MRX-1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3287379 ↗ |
| Known as | MRX-I | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02269319 ↗ |
| Action | Inhibit | “It inhibits bacterial growth by interfering with protein synthesis through its translational inhibitory effect on bacteria.” NCT06811025 ↗ |
| Modality | Small molecule | “novel oxazolidinone antibiotic” NCT06811025 ↗ |
| Route | Oral | “Oral MRX-I 800mg given twice a day for 10 days” NCT02269319 ↗ |